Seven Fleet Capital Management LP Acquires New Shares in Palisade Bio, Inc. $PALI

by · The Markets Daily

Seven Fleet Capital Management LP bought a new position in Palisade Bio, Inc. (NASDAQ:PALI – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 327,500 shares of the company’s stock, valued at approximately $770,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in shares of Palisade Bio during the 4th quarter valued at about $28,318,000. Commodore Capital LP bought a new stake in shares of Palisade Bio during the 4th quarter valued at $26,896,000. Janus Henderson Group PLC purchased a new stake in Palisade Bio in the fourth quarter worth about $24,822,000. RA Capital Management L.P. purchased a new stake in shares of Palisade Bio in the 4th quarter worth approximately $16,742,000. Finally, Eversept Partners LP bought a new stake in Palisade Bio during the 4th quarter valued at about $12,670,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PALI. HC Wainwright started coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings downgraded shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wolfe Research began coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Stifel Nicolaus started coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.20.

View Our Latest Stock Report on Palisade Bio

Palisade Bio Price Performance

Shares of PALI stock opened at $1.87 on Friday. The stock’s 50-day moving average is $1.97 and its 200 day moving average is $1.90. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.85. The company has a market cap of $324.59 million, a P/E ratio of -1.85 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts anticipate that Palisade Bio, Inc. will post -0.21 EPS for the current year.

About Palisade Bio

(Free Report)

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

Read More

Want to see what other hedge funds are holding PALI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palisade Bio, Inc. (NASDAQ:PALI – Free Report).